Context Therapeutics Inc

NASDAQ:CNTX   3:59:19 PM EDT
0.58
-0.02 (-3.82%)
Products

Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of Orserdu

Published: 01/31/2023 13:50 GMT
Context Therapeutics Inc (CNTX) - Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of Orserdu™ (elacestrant) in Er+, Her2-, Esr1-mutated Breast Cancer.
Context Therapeutics - Orserdu is Being Evaluated in Combination With Context's Ona-xr in Ongoing Elona Trial.